EDIT
Price
$3.11
Change
-$0.06 (-1.89%)
Updated
Oct 9, 01:48 PM (EDT)
28 days until earnings call
PRME
Price
$3.61
Change
-$0.17 (-4.50%)
Updated
Oct 9, 02:05 PM (EDT)
23 days until earnings call
Ad is loading...

EDIT vs PRME

Header iconEDIT vs PRME Comparison
Open Charts EDIT vs PRMEBanner chart's image
Editas Medicine
Price$3.11
Change-$0.06 (-1.89%)
Volume$100
CapitalizationN/A
Prime Medicine
Price$3.61
Change-$0.17 (-4.50%)
Volume$2.3K
CapitalizationN/A
View a ticker or compare two or three
EDIT vs PRME Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
EDIT vs. PRME commentary
Oct 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongSell and PRME is a Hold.

COMPARISON
Comparison
Oct 09, 2024
Stock price -- (EDIT: $3.16 vs. PRME: $3.78)
Brand notoriety: EDIT and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 77% vs. PRME: 139%
Market capitalization -- EDIT: $287.02M vs. PRME: $415.31M
EDIT [@Biotechnology] is valued at $287.02M. PRME’s [@Biotechnology] market capitalization is $415.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 4 bearish.
  • PRME’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, PRME is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -3.21% price change this week, while PRME (@Biotechnology) price change was +9.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 26, 2025.

PRME is expected to report earnings on Nov 01, 2024.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($415M) has a higher market cap than EDIT($287M). PRME YTD gains are higher at: -57.336 vs. EDIT (-68.756). PRME (-204.68M) and EDIT (-207.21M) have comparable annual earnings (EBITDA) . EDIT has more cash in the bank: 279M vs. PRME (163M). EDIT has less debt than PRME: EDIT (38.7M) vs PRME (41.6M). EDIT has higher revenues than PRME: EDIT (67M) vs PRME (591K).
EDITPRMEEDIT / PRME
Capitalization287M415M69%
EBITDA-207.21M-204.68M101%
Gain YTD-68.756-57.336120%
P/E RatioN/AN/A-
Revenue67M591K11,337%
Total Cash279M163M171%
Total Debt38.7M41.6M93%
FUNDAMENTALS RATINGS
EDIT vs PRME: Fundamental Ratings
EDIT
PRME
OUTLOOK RATING
1..100
5785
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9065
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for PRME (79) in the null industry. This means that EDIT’s stock grew somewhat faster than PRME’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that EDIT’s stock grew similarly to PRME’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that EDIT’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (65) in the null industry is in the same range as EDIT (90) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 21 days ago
79%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 7 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL225.774.08
+1.84%
Apple
TSLA244.503.67
+1.52%
Tesla
SPY573.175.37
+0.95%
SPDR® S&P 500® ETF Trust
BTC.X62131.970000-104.691410
-0.17%
Bitcoin cryptocurrency
GME20.71-0.19
-0.91%
GameStop Corp

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-1.40%
NTLA - EDIT
75%
Closely correlated
+0.39%
CRSP - EDIT
68%
Closely correlated
-0.64%
BEAM - EDIT
67%
Closely correlated
-0.64%
ALLO - EDIT
55%
Loosely correlated
+6.20%
ALEC - EDIT
55%
Loosely correlated
+2.43%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been closely correlated with NTLA. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if PRME jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+3.56%
NTLA - PRME
67%
Closely correlated
+0.39%
BEAM - PRME
64%
Loosely correlated
-0.64%
ABCL - PRME
58%
Loosely correlated
-2.47%
CRSP - PRME
57%
Loosely correlated
-0.64%
ALLO - PRME
55%
Loosely correlated
+6.20%
More